Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.71 USD | +1.64% | -3.81% | +20.08% |
Financials (USD)
Sales 2024 * | 38.27M | Sales 2025 * | 31.72M | Capitalization | 929M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -237M | EV / Sales 2024 * | 16 x |
Net cash position 2024 * | 318M | Net cash position 2025 * | 254M | EV / Sales 2025 * | 21.3 x |
P/E ratio 2024 * |
-4.81
x | P/E ratio 2025 * |
-4.25
x | Employees | 284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.38% |
Latest transcript on Bicycle Therapeutics plc
1 day | +1.64% | ||
1 week | -3.81% | ||
Current month | -7.42% | ||
1 month | -7.42% | ||
3 months | -4.32% | ||
6 months | +59.28% | ||
Current year | +20.08% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lee
CEO | Chief Executive Officer | 55 | 15-08-31 |
Alethia Young
DFI | Director of Finance/CFO | 45 | 23-07-16 |
Alistair Milnes
COO | Chief Operating Officer | 50 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pierre Legault
CHM | Chairman | 63 | 19-03-17 |
Director/Board Member | 61 | 21-03-16 | |
Richard Kender
BRD | Director/Board Member | 68 | 19-07-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.03% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-20 | 21.71 | +1.64% | 89,406 |
24-05-17 | 21.36 | -3.70% | 124,459 |
24-05-16 | 22.18 | -0.81% | 168,812 |
24-05-15 | 22.36 | +2.33% | 386,468 |
24-05-14 | 21.85 | -3.19% | 184,002 |
Delayed Quote Nasdaq, May 20, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.08% | 929M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.41% | 21.6B | |
-12.38% | 22.31B | |
-6.87% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- BCYC Stock